stockrow
Saturday 7 November 2026
Export MDXG’s income statement to Excel — free account
MiMedx Group, Inc
MDXG Healthcare Biotechnology
MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024.
- Revenue
- −45.2%
- EPS
- −154.1%
- Free cash flow
- −87.2%
- Total debt
- −6.80%
Quarter to September 2026, against a year earlier
3.31
0.03
+0.91%
Follow MDXG
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
20.52 | 18.81 | 96.25 | 0.00 |
P/S ratio |
2.39 | 1.51 | 1.60 | 2.24 | |
P/FCF ratio |
13.71 | 8.46 | 12.81 | 35.73 | |
P/Operating CF |
40.09 | 312.06 | (56.82) | 173.45 | |
P/B ratio |
3.90 | 2.41 | 2.63 | 3.22 | |
Price to Tangible BV |
4.49 | 2.79 | 3.08 | 3.77 | |
EV/Sales |
2.04 | 1.14 | 1.27 | 1.90 | |
EV/EBITDA |
10.82 | 8.40 | 22.07 | 0.00 | |
EV/Operating CF |
11.52 | 6.29 | 9.76 | 27.78 | |
EV/FCF |
11.68 | 6.41 | 10.14 | 30.29 | |
Quick Ratio |
3.76 | 4.62 | 4.60 | 3.67 | |
Current Ratio |
4.32 | 5.39 | 5.33 | 4.35 | |
Net Debt/EBITDA |
(6.10) | 9.85 | 7.01 | 11.80 | |
Debt/Assets |
5.24% | 5.70% | 6.12% | 0.00% | |
Debt/Equity |
0.07 | 0.07 | 0.08 | 0.00 | |
Asset Turnover |
1.38 | 1.34 | 1.24 | 1.04 | |
Operating CF/Net income |
1.64 | (0.17) | 0.67 | (0.45) | |
Capex/Depreciation |
(0.08) | (0.40) | (0.41) | (0.13) | |
Research and Development Expense of Revenue |
4.03% | 7.02% | 4.31% | 4.49% | |
Selling, General and Administrative Expense of Revenue |
61.88% | 90.24% | 92.88% | 93.63% | |
Intangible Assets out of Total Assets |
0.10 | 0.11 | 0.11 | 0.12 | |
Share Based Compensation of Revenue |
2.09% | (2.88%) | 1.40% | 5.16% | |
Graham Net Nets |
0.19 | 0.30 | 0.25 | 0.20 | |
Graham Number |
3.59 | 2.78 | 1.15 | 0.00 | |
Earnings Yield |
4.87% | 5.32% | 1.04% | (2.78%) | |
Free Cash Flow Yield |
7.29% | 11.82% | 7.81% | 2.80% | |
Revenue per Share |
0.80 | 0.40 | 0.44 | 0.43 | |
Operating CF per Share |
0.17 | 0.01 | (0.07) | 0.03 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.17 | 0.01 | (0.07) | 0.03 | |
Cash per Share |
1.12 | 1.08 | 0.92 | 0.83 | |
Shareholders Equity per Share |
1.74 | 1.64 | 1.46 | 1.45 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.74 | 1.64 | 1.46 | 1.45 | |
Free Cash Flow |
24.71 | 1.24 | (10.65) | 3.73 | |
Working Capital |
213.21 | 195.78 | 166.87 | 144.20 | |
Capital Expenditures |
(0.25) | (0.64) | (0.63) | (0.19) | |
Net Current Asset Value |
191.37 | 174.59 | 140.37 | 133.76 | |
EV/EBIT |
13.34 | 11.22 | 51.47 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
15.66 | 14.81 | 65.02 | 0.00 | |
| Other line items | |||||
Average Receivables |
65.77 | 54.16 | 55.26 | 57.73 | |
Average Payables |
10.97 | 10.17 | 8.40 | 11.62 | |
Average Inventory |
24.57 | 25.15 | 22.91 | 24.30 | |
Average Assets |
303.28 | 289.55 | 286.05 | 291.77 | |
Average Common Equity |
224.83 | 222.86 | 216.31 | 225.01 |
Columns are period end dates · fundamentals updated 2 Nov 2026